Earning Analysis
Welcome to our in-depth analysis of Liquidia Corp(LQDA) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Liquidia Corp earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
| FY2025Q3 | 2025-11-03 | Pre-Market | -0.45 | -0.04 | +91.11 | 19.46M | 54.34M | +179.22 | +3.53 | +5.09 |
| FY2025Q2 | 2025-08-12 | Pre-Market | -0.43 | -0.49 | -13.95 | 3.89M | 8.84M | +126.96 | +13.68 | +22.41 |
| FY2025Q1 | 2025-05-08 | Pre-Market | -0.42 | -0.45 | -7.14 | 3.23M | 3.12M | -3.26 | -1.16 | +2.96 |
| FY2024Q4 | 2025-03-19 | Pre-Market | -0.38 | - | - | 4.60M | 2.92M | -36.55 | +1.22 | +5.83 |
| FY2024Q2 | 2024-08-07 | Pre-Market | -0.35 | -0.37 | -5.71 | 9.61M | 3.66M | -61.92 | -3.44 | +20.16 |
| FY2024Q1 | 2024-05-13 | - | -0.32 | -0.54 | -68.75 | 4.39M | 2.97M | -32.28 | +0.66 | +5.39 |
| FY2023Q4 | 2024-03-13 | - | -0.23 | -0.42 | -82.61 | 4.73M | 4.53M | -4.24 | +5.36 | +14.59 |
| FY2023Q3 | 2023-11-07 | - | -0.20 | -0.24 | -20.00 | 4.33M | 3.68M | -15.13 | +3.66 | -3.51 |
| FY2023Q2 | 2023-08-10 | - | -0.17 | -0.36 | -111.76 | 4.32M | 4.79M | +10.82 | +3.14 | -9.54 |
| - | 2023-03-16 | - | -0.17 | -0.09 | +47.06 | - | - | - | +15.25 | +7.86 |
LQDA Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Liquidia Corp reported performance for FY2025Q3, announced on 2025-11-03. The company achieved an EPS of -0.04, compared to analyst estimates of -0.45 by 91.11% . Revenue for the quarter reached 54.34M compared to expectations of 19.46M by 179.22% .
The stock price reacted with a 3.53% one-day change and a 5.09% five-day change following the earnings release. These movements reflect market reaction in Liquidia Corp growth trajectory and strategic initiatives.
LQDA Earnings Forecast
Looking ahead, Liquidia Corp(LQDA) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q4 project quarter revenue of 94.30M and an EPS of -0.20.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Upward by 116.35%, while EPS estimates have been Revise Downward by -51.66%. For the upcoming Q4 2025, revenue estimates have been adjusted Revise Upward by 110.92% . These revisions correlate with a 17.57% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Liquidia Corp long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between LQDA's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Upward
+116.35%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-51.66%
In Past 3 Month
Revenue Estimates for Q4 2025
Revise Upward
+110.92%
In Past 3 Month
Stock Price
Go Up
+17.57%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:150.10M
--
EPS Estimate-Annual FY 2025:-0.78
—
Stock Price33.92
LQDA Revenue and EPS Performance: A Historical Perspective
Liquidia Corp revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q3 (2025-11-03,Pre-Market):
EPS: -0.04 (Actual) vs.-0.45 (Estimate) (91.11%)
Revenue: 54.34M (Actual) vs. 19.46M (Estimate) (179.22%)
Price Reaction: 3.53%(1-Day), 5.09%(5-Day)
FY2025Q2 (2025-08-12,Pre-Market):
EPS: -0.49 (Actual) vs.-0.43 (Estimate) (-13.95%)
Revenue: 8.84M (Actual) vs. 3.89M (Estimate) (126.96%)
Price Reaction: 13.68%(1-Day), 22.41%(5-Day)
FY2025Q1 (2025-05-08,Pre-Market):
EPS: -0.45 (Actual) vs.-0.42 (Estimate) (-7.14%)
Revenue: 3.12M (Actual) vs. 3.23M (Estimate) (-3.26%)
Price Reaction: -1.16%(1-Day), 2.96%(5-Day)
Earnings Reaction
The chart below shows how LQDA performed 10 days before and after its earnings report, based on data from the past quarters. Typically, LQDA sees a -3.64% change in stock price 10 days leading up to the earnings, and a +0.11% change 10 days following the report. On the earnings day itself, the stock moves by +4.19%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2025, the stock changed 10.67% on the day following the earnings release and then changed by 12.61% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
Liquidia Corp (LQDA) Q3 2025 Earnings Call Summary
Positive
2025-11-03
The earnings call highlights strong YUTREPIA adoption, positive cash flow, and profitability ahead of schedule. Although there are execution and litigation risks, the company's strategic plans and payer coverage expansion indicate growth potential. The Q&A session shows positive sentiment from analysts, with management addressing concerns effectively. Overall, the positive financial performance and market strategy outweigh the potential risks, suggesting a stock price increase.
Liquidia Corp (LQDA) Q2 2025 Earnings Call Summary
Neutral
2025-08-12
The earnings call summary shows a mix of positive and cautious elements. Product development is advancing, with potential growth levers identified. However, management's lack of clarity on key data points and the absence of specific financial projections raise concerns. The Q&A reveals an accelerating uptake of YUTREPIA but also highlights uncertainties in data disclosure and reliance on channel inventory for revenue. These factors balance each other out, leading to a neutral sentiment prediction for the stock price movement over the next two weeks.
Liquidia Corp (LQDA) Q4 2024 Earnings Call Summary
Negative
2025-03-19
The earnings call summary reveals a negative sentiment due to declining revenue, increased costs, and a significant net loss. The Q&A section highlights positive feedback on product differentiation and potential market approval, but lacks clarity on pricing and dose response. The expansion of financing is a positive factor, but overall financial health concerns and unclear guidance lead to a negative outlook.
Liquidia Corporation (LQDA) Q3 2024 Earnings Call Summary
Negative
2024-11-13
The earnings call reveals several negative factors: ongoing litigation risks with the FDA and United Therapeutics, financial strain from increased losses, and operational risks due to rising R&D expenses. Despite some positive financial aspects like a cash influx and revenue growth, the uncertainties surrounding YUTREPIA's approval and competitive pressures overshadow these. The Q&A further highlights management's inability to provide clear guidance on critical issues, exacerbating investor concerns. Thus, the stock price is likely to experience a negative reaction in the short term.
Liquidia Corporation (LQDA) Q2 2024 Earnings Call Summary
Negative
2024-08-08
The earnings call reveals several concerning factors: declining revenue, increased operational costs, and a widening net loss. There is also uncertainty regarding FDA approval for YUTREPIA and no shareholder return plan. The Q&A session highlights management's evasiveness on critical issues, adding to investor uncertainty. Despite a strong cash position, these negatives outweigh positives, suggesting a negative stock price movement.
People Also Watch
FAQ
What were the key highlights of LQDA’s latest earnings report for FY2025Q3?
How did LQDA’s stock price react after the FY2025Q3 earnings release?
What are the revenue and EPS estimates for LQDA for 2025/Q4?
How does LQDA’s stock price correlate with earnings forecast revisions?
What should investors expect from LQDA’s next earnings report?